StockpollyBeta
Get App
Popularity #1,298
ALLO · NASDAQ · Biotechnology

Allogene Therapeutics (ALLO)

Develops off-the-shelf CAR T candidates for cancer and autoimmune disease.

$1.67
vs last close−0.04 (−2.34%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000000000005
Cost of revenue4045045334031330
Gross profit−40−4−50−45−3−3−40−31−3−35
598566212757621714394352
Research & development465552504545504031292931
171717161616151414141421
General & administrative171717161616151414141421
Other expenses−413−4−45−34−3−3−38−31−300
Operating income−63−85−70−71−72−60−65−57−45−42−46−47
1−45551564434
Interest income665573664445
Interest expense000000000000
Other non-operating income−1−13−5−5−6−1−6−6−4−4−4−5
Income before tax−62−89−65−66−66−59−60−51−41−39−43−43
Income tax expense000000000000
Net income from continuing operations−62−89−65−66−66−60−60−51−41−39−43−43
Net income−62−89−65−66−66−60−60−51−41−39−43−43
EPS, basic−$0.37−$0.51−$0.38−$0.35−$0.32−$0.28−$0.28−$0.23−$0.19−$0.17−$0.18−$0.13
EPS, diluted−$0.37−$0.51−$0.38−$0.35−$0.32−$0.28−$0.28−$0.23−$0.19−$0.17−$0.18−$0.13
Weighted average shares, basic168168169190209211215219222221240329
Weighted average shares, diluted168168169190209211215219222221240329
EBITDA−59−68−61−63−63−56−56−48−38−35−39−40
Depreciation & amortization434433333333
EBIT−62−72−65−66−66−59−60−51−41−38−42−42